HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM.

AbstractOBJECTIVE:
To determine whether the angiotensin-converting enzyme (ACE) inhibitor fosinopril can favorably alter cardiac function in non-insulin-dependent diabetes mellitus NIDDM) patients who have either normal blood pressure (BP) or mild, untreated hypertension.
RESEARCH DESIGN AND METHODS:
Fifty-five NIDDM subjects with normal BP or mild, untreated hypertension were randomized to treatment with the ACE-inhibitor fosinopril or placebo for 6 months in a randomized, double-blind trial to determine the effect of fosinopril on echocardiographic measurements.
RESULTS:
Left ventricular mass index (LVMI) fell by 6.5 +/- 4.7% (mean +/- SD) with fosinopril and increased by 8.6 +/- 3.5% during placebo treatment (P < 0.02), and isovolumic relaxation time improved significantly in those with elevated baseline levels (P = 0.02). Systolic BP fell significantly, but this did not correlate with the change in LVMI, suggesting a possible direct action of fosinopril on the heart.
CONCLUSIONS:
Fosinopril appears to have significant cardiac benefits in patients with NIDDM who have normal or mildly elevated BP. These benefits are achieved without adversely affecting renal status and without impairing metabolic control of diabetes.
AuthorsI M Holdaway, G D Gamble, G A Sanders, S C Greaves, E M Ellis-Pegler, N Sharpe
JournalDiabetes care (Diabetes Care) Vol. 17 Issue 12 Pg. 1476-9 (Dec 1994) ISSN: 0149-5992 [Print] United States
PMID7882821 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Insulin
  • Lipids
  • Fosinopril
Topics
  • Blood Glucose (analysis)
  • Blood Pressure (drug effects)
  • Diabetes Mellitus, Type 2 (blood, drug therapy, physiopathology)
  • Double-Blind Method
  • Echocardiography, Doppler
  • Female
  • Fosinopril (pharmacology, therapeutic use)
  • Heart (drug effects)
  • Humans
  • Hypertension (complications, drug therapy)
  • Insulin (blood)
  • Lipids (blood)
  • Male
  • Middle Aged
  • Multivariate Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: